Tirzepatide could result in net lifetime health care costs of more than $16 trillion in the U.S. if all people eligible to ...

Rybelsus, the oral form of Semaglutide launched by Novo Nordisk in January 2022, has grown from Rs 26 crore to Rs 412 crore, ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a promising ...

Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.